Download PDF
Zentralbl Chir 2019; 144(03): 235-241
DOI: 10.1055/a-0882-6545
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Entwicklungen in der regionalen Behandlung von peritonealen und pleuralen Tumoren (inkl. HIPEC und HITOC)

Recent Developments in the Regional Treatment of Peritoneal and Pleural Tumours (incl. HIPEC and HITOC)
Pompiliu Piso
1   Klinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brüder, Regensburg, Deutschland
,
Hans Stefan Hofmann
2   Klinik für Thoraxchirurgie, Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
05 June 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die multimodale Therapie von begrenzten peritonealen Metastasen kann bei ausgewählten Tumorentitäten die Prognose der Patienten günstig beeinflussen, sollte eine komplette Resektion erfolgen (Pseudomyxoma peritonei, malignes peritoneales Mesotheliom, kolorektales Karzinom, Magenkarzinom und Ovarialkarzinom). Oft wird additiv eine hypertherme intraperitoneale Chemotherapie (HIPEC) intraoperativ durchgeführt. Wenn die Behandlung in erfahrenen (und zertifizierten) Zentren durchgeführt wird, ist diese mit einer niedrigen Letalität verbunden. Die intrakavitäre hypertherme Perfusionschemotherapie (HITOC) in der Pleura kann zur Behandlung bösartiger Pleuratumoren eingesetzt werden. Wesentliche Indikationen sind das Pleuramesotheliom oder der sekundäre Pleurabefall durch ein Thymom (Stadium IV a). Die HITOC wird in Einzelfällen auch bei Patienten mit einer Pleurakarzinose durchgeführt. Beide Verfahren (HIPEC und HITOC) sind komplex und der genaue Stellenwert der lokoregionalen hyperthermen Chemotherapie muss durch weitere prospektiv randomisierte Studien geklärt werden.

Abstract

The multimodal treatment of limited peritoneal metastases may improve prognosis in selected patients (pseudomyxoma peritonei, malignant peritoneal mesothelioma, colorectal, gastric and ovarian cancer) provided complete cytoreduction can be performed. Additive intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is often performed. If the treatment is undertaken in experienced (and certified) centres, associated mortality is low. Intrapleural hyperthermic chemoperfusion (HITOC) can be performed in patients with pleural malignancies, mainly for malignant pleural mesothelioma or metastases from a thymoma. In single patients, pleural metastases from gastrointestinal malignancies might be an indication. Both therapies (HIPEC and HITOC) are complex and their exact role has to be defined within further prospective randomised trials.

Schlüsselwörter

Peritonealkarzinose - Peritonektomie - Chemotherapie

Key words

metastasis - chemotherapy - peritoneal carcinomatosis
 

  • Literatur

  • 1 Spratt JS, Adcock RA, Muskovin M. et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: 256-260
    PubMedGoogle Scholar
  • 2 Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 2010; 7: 108-115
    CrossrefPubMedGoogle Scholar
  • 3 Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42
    CrossrefPubMedGoogle Scholar
  • 4 Yan TD, Links M, Fransi S. et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy–a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 2007; 14: 2270-2280
    CrossrefPubMedGoogle Scholar
  • 5 Chua TC, Yan TD, Saxena A. et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 2009; 249: 900-907
    CrossrefPubMedGoogle Scholar
  • 6 Verwaal VJ, van Ruth S, de Bree E. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743
    CrossrefPubMedGoogle Scholar
  • 7 Elias D, Gilly F, Boutitie F. et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68
    CrossrefPubMedGoogle Scholar
  • 8 Yang XJ, Huang CQ, Suo T. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18: 1575-1581
    CrossrefPubMedGoogle Scholar
  • 9 van Driel WJ, Koole SN, Sikorska K. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378: 230-240
    CrossrefPubMedGoogle Scholar
  • 10 Quenet F. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018; 36 (Suppl.) abstr. LBA. 3503
    PubMedGoogle Scholar
  • 11 Glockzin G, Zeman F, Croner RS. et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC Trial. Clin Colorectal Cancer 2018; 17: 285-296
    CrossrefPubMedGoogle Scholar
  • 12 Piso P, Stierstorfer K, Gerken M. et al. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis 2018; 33: 1559-1567
    CrossrefPubMedGoogle Scholar
  • 13 Piso P, Nedelcut SD, Rau B. Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol 2019; 26: 148-154
    CrossrefPubMedGoogle Scholar
  • 14 Feferman Y, Solomon D, Bhagwandin S. et al. Sites of recurrence after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis from colorectal and appendiceal adenocarcinoma: a tertiary center experience. Ann Surg Oncol 2019; 26: 482-489 doi:10.1245/s10434-018-6860-4
    CrossrefPubMedGoogle Scholar
  • 15 Alzahrani NA, Valle SJ, Fisher OM. et al. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional experience. J Surg Oncol 2019; 119: 336-346 doi:10.1002/jso.25277
    CrossrefPubMedGoogle Scholar
  • 16 Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2009; 7: 5
    CrossrefPubMedGoogle Scholar
  • 17 Yellin A, Simansky DA, Paley M. et al. Hyperthermic pleural perfusion with cisplatin: early clinical experience. Cancer 2001; 92: 2197-2203
    CrossrefPubMedGoogle Scholar
  • 18 De Bree E, van Ruth S, Baas P. et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480-487
    CrossrefPubMedGoogle Scholar
  • 19 Sugarbaker DJ, Gill RR, Yeap BY. et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013; 145: 955-963
    CrossrefPubMedGoogle Scholar
  • 20 Yellin A, Simansky DA, Ben-Avi R. et al. Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience. J Thorac Cardiovasc Surg 2013; 145: 83-89
    CrossrefPubMedGoogle Scholar
  • 21 Matsuzaki Y, Shibata K, Yoshioka M. et al. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 1995; 59: 127-131
    CrossrefPubMedGoogle Scholar
  • 22 Feng X, Zhu L, Xiong X. et al. Therapeutical effect of intrapleural perfusion with hyperthermic chemotherapy on malignant pleural effusion under video-assisted thoracoscopic surgery. Int J Hyperthermia 2018; 34: 479-485 doi:10.1080/02656736.2017.1340676
    CrossrefPubMedGoogle Scholar
  • 23 Ba M, Long H, Wang Y. et al. Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion. J Cancer Res Clin Oncol 2013; 139: 2005-2012
    CrossrefPubMedGoogle Scholar
  • 24 Ashraf-Kashani N, Bell J. Haemodynamic changes during hyperthermic intra-thoracic chemotherapy for pseudomyxoma peritonei. Int J Hyperthermia 2017; 33: 675-678
    CrossrefPubMedGoogle Scholar
  • 25 Ababneh R, Piso P, Hofmann HS. et al. An invasive treatment of Pseudomyxoma peritonei with intrathoracic involvement. Maedica (Buchar) 2016; 11: 72-75
    PubMedGoogle Scholar
  • 26 Papadia A, Morotti M. Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature. Arch Gynecol Obstet 2013; 287: 733-741
    CrossrefPubMedGoogle Scholar
  • 27 Chen MY, Chiles C, Loggie BW. et al. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Oncol 1997; 66: 19-23
    CrossrefPubMedGoogle Scholar
  • 28 Pestieau SR, Esquivel J, Sugarbaker PH. Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome. Ann Surg Oncol 2000; 7: 199-203
    CrossrefPubMedGoogle Scholar
  • 29 Schneider MA, Eden J, Pache B. et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg 2018; 268: 845-853
    CrossrefPubMedGoogle Scholar